Background: Autonomic dysfunction is commonly encountered after acute ischemic stroke (AIS) and may influence both functional recovery and survival. Heart rate variability (HRV) provides a non-invasive measure of autonomic balance, but its temporal evolution and prognostic significance in AIS remain insufficiently evaluated. Methods: In this prospective observational study, 148 AIS patients (mean age of 65.93 ± 9.19 years) underwent HRV assessment at baseline, one month, and three months follow-up, between January 2022 and October 2024. Time and frequency domain parameters, including Standard Deviation of NN intervals (SDNN), Low-Frequency (LF) power, High-Frequency (HF) power, and LF/HF ratio, were analyzed. Functional outcome was assessed using the modified Rankin Scale (mRS), with a good outcome defined as mRS ≤ 2. Multivariable logistic regression identified independent predictors of poor outcome (mRS > 2) at each time point. Mortality was recorded at one and three months, and potential predictors were evaluated. Results: Over three months, SDNN increased by 34.84% (p < 0.001), HF power rose by 22.26% (p < 0.001), LF power decreased by 21.61% (p < 0.001), and LF/HF ratio declined by 35.41% (p < 0.001), indicating a shift toward parasympathetic predominance. Higher SDNN correlated strongly with better functional status and was an important predictor of favorable outcome at all time points (p < 0.001). Higher LF/HF ratio predicted poor outcome at baseline (p < 0.01) and three months (p < 0.001). At three months, mortality reached 12.2%, with significant predictors including coronary artery disease (CAD), heart failure (HF), chronic kidney disease (CKD), and altered HRV parameters. Conclusions: Post-stroke recovery is characterized by the progressive restoration of autonomic balance, with higher SDNN and lower LF/HF associated with improved functional recovery and survival. HRV analysis offers valuable prognostic insight and may aid in risk stratification after AIS.

Background and Objectives: The obesity paradox in maintenance hemodialysis (MHD) patients (better survival of obese as compared to non-obese patients in MHD) remains controversial, with many published papers supporting the idea that higher BMI is protective. Data from Eastern Europe, in particular from the elderly population on hemodialysis, are limited. The aim of this study was to describe the distribution of body weight status and cardiometabolic comorbidities and to evaluate the association of BMI categories with all-cause mortality in a multi-center Romanian hemodialysis cohort. Materials and Methods: We conducted a retrospective cohort study of 679 patients with end-stage kidney disease (ESKD) undergoing maintenance haemodialysis in eight Romanian centers. All patients received thrice-weekly treatments (≥4 h/session) using high-flux dialysers. Baseline demographic, clinical, laboratory, and echocardiographic data were extracted from dialysis records. Survival across BMI groups was assessed using Kaplan–Meier curves and the log-rank test. Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause mortality, with normal weight as the reference category. Multivariable models incorporated progressive adjustment for age, sex, dialysis vintage, diabetes, major cardiovascular comorbidities, and ESKD-related factors, including anemia parameters and CKD–mineral and bone disorder (CKD-MBD) markers. Results: A total of 679 haemodialysis patients were included (mean age 57.2 ± 12.9 years; 59.1% male); 52.7% were normal weight, 28.9% overweight, and 18.4% obese. During follow-up, 360 patients (53.0%) died, with similar crude mortality across BMI groups (normal weight 51.7%, overweight 55.1%, obese 53.6%; p > 0.05). In univariate Cox analyses, older age, obesity, hypoalbuminaemia, elevated CRP, hyperphosphataemia, peripheral and cerebrovascular disease, diabetes, low dialysis adequacy (eKt/V < 1.2), and lower ultrafiltration were associated with higher mortality, whereas preserved LVEF (≥50%) was protective. In multivariable analyses, independent predictors of mortality included older age (HR 1.042 per year, p < 0.001), obesity (HR 1.411, p = 0.045), elevated CRP (HR 1.781, p < 0.001), diabetes (HR 1.775, p < 0.001), inadequate dialysis dose (eKt/V < 1.2; HR 1.343, p = 0.029), and preserved LVEF remained protective (HR 0.665, p = 0.013). The Kaplan–Meier analysis showed significantly lower survival with increasing BMI: median survival was 7.56 years in normal-weight patients, 4.56 years in overweight patients, and 3.92 years in obese individuals (log-rank p < 0.05). Conclusions: In this Romanian cohort of multicenter hemodialysis patients, obesity as measured by BMI was associated with an increased incidence of all-cause mortality, while overweight did not confer a clear survival advantage over normal weight. These findings call into question the classic hemodialysis obesity paradox and support a more cautious interpretation of the increased BMI.

Background: Obesity, type 2 diabetes mellitus, and hypertension are increasingly prevalent components of metabolic syndrome and major contributors to cardiovascular disease and chronic kidney disease progression; however, in end-stage kidney disease an “obesity paradox” has been described, with higher body mass index (BMI) sometimes associated with improved survival on hemodialysis. Material and methods: This retrospective, single-center Eastern European cohort study aimed to characterize mortality and its causes around hemodialysis initiation in the contemporary era of cardiometabolic prevention and to test whether the obesity paradox persists at this high-risk transition. Adult patients initiating dialysis at the “Pius Brânzeu” Emergency Clinical Hospital (Timișoara, Romania) between January 2022 and December 2025 (n = 268; median age 66 years; 61% male; median eGFR 6.4 mL/min/1.73 m²) were analyzed using Kaplan–Meier methods and Cox regression, with comprehensive baseline clinical, laboratory, echocardiographic, medication, infection, and vascular access data; follow-up was obtained at 3, 6, 12, 24, and 36 months. Results: Late referral was common (61% < 3 months of nephrology follow-up), dialysis initiation was predominantly urgent (only 16% scheduled), and central venous catheters were the main access (81%), with substantial comorbidity burden (cardiovascular disease 71%, hypertension 90%) and frequent infections at initiation. BMI categories were non-obese (<25 kg/m², 30%), overweight (25–29.9 kg/m², 48%), and obese (≥30 kg/m², 22%); diabetes prevalence rose with BMI (32% to 58%). Unadjusted mortality did not differ by BMI (19.8%, 18.8%, 15.3%; log-rank p = 0.622), yet multivariable Cox models showed overweight status independently reduced mortality (HR 0.22 at 3 months, 0.29 at 1 year, 0.31 at 3 years vs. non-obese), whereas obesity was not protective. Early mortality was driven mainly by age ≥ 65 years, while diabetes and chronic obstructive pulmonary disease predicted later mortality; longer pre-dialysis follow-up time was strongly protective (HR per year 0.70 at 3 years), and higher intact parathyroid hormone showed an inverse association with 1-year mortality. Conclusions: These findings show a modified obesity paradox at dialysis initiation in which moderate excess weight, but not obesity, is associated with improved adjusted survival, underscoring the clinical importance of earlier nephrology engagement and individualized nutritional and risk-factor management during the pre-dialysis and early dialysis periods.

The coronavirus pandemic has significantly impacted a substantial part of the global population, and the cardiovascular repercussions of COVID-19 infection have been unveiled for the first time. While the arrhythmogenic effects of the severe inflammatory syndrome associated with the infection are well-established, another critical cause of arrhythmias, particularly ventricular arrhythmias such as ventricular tachycardia, torsades de pointes, or ventricular fibrillation, which can result in cardiac arrest, is the pharmacological treatment employed to manage the disease in hospitalized patients. Among all arrhythmogenic mechanisms, the QT interval prolongation is the most alarming. This review aims to provide a more in-depth exploration of these effects and the potential mechanisms underlying their occurrence.